North American Society for Interventional Thyroidology Statement on Directed Ablative Therapy for the Management of Cervical Recurrence of Papillary Thyroid Cancer
Methodological detailsmultidisciplinary task force, evidence review and expert consensus
- Multidisciplinary task force
- Evidence review and expert consensus
Recommendations
As issued by the authors
Directed ablative therapy (DAT) is recommended for patients who refuse surgery, are at high surgical risk, have RAI-refractoriness, or have small-volume nodal disease where the risk-benefit balance of RAI is unfavorable
For curative intent, DAT may be considered for recurrent papillary thyroid cancer (PTC) with a limited number (≤3) of small-volume (≤2 cm) nodes without high-risk molecular features
No study stratified outcomes by PTC histological subtype; apply to higher-risk subtypes with caution
A preprocedural checklist and structured follow-up are essential to ensure safety and effectiveness
Original publication
North American Society for Interventional Thyroidology Statement on Directed Ablative Therapy for the Management of Cervical Recurrence of Papillary Thyroid Cancer. Endocr Pract. Published 4 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →